ArticleNPJ breast cancer2025
Longitudinal changes in gut microbiota composition during endocrine therapy in hormone receptor-positive breast cancer patients.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The dialogue between breast cancer and microorganisms.Frontiers in cellular and infection microbiology · 2026Review
- Microbiome-Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response.BioMed research international · 2026Review
- The microbiome as a systems-level regulator of immune, metabolic, neural, and endocrine signaling in cancer.Frontiers in immunology · 2026Review
- Estrobolome dysbiosis in canine mammary gland tumors:Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This prospective study of 90 breast cancer patients examined gut microbiota composition relative to hormone receptor status and endocrine therapy changes. Initial analysis suggested hormone receptor-negative patients had higher Fusobacteriaceae and Fusobacterium abundance, while hormone receptor-positive patients showed Ruminiclostridium enrichment, though differences lacked statistical significance after correction. Hormone receptor-positive patients without lymph node metastasis demonstrated potentially greater microbial diversity, but associations were non-significant after multiple comparison correction. Longitudinal analysis of 52 hormone receptor-positive patients revealed the most robust finding: statistically significant Blautia increases after hormone therapy and aromatase inhibitor treatment. Tamoxifen showed trends toward increased Lachnospiraceae but lost significance after correction due to small sample size. LHRH agonist treatment demonstrated significant Dialister and Megasphaera increases. This study identified limited but robust associations between gut microbiota and endocrine treatments, with Blautia as the most consistently affected genus across multiple therapies, though most findings require validation in larger cohorts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.